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Abstract 
We present a case of a 48 year old HIV patient, who had recurrent episodes of ascites since 
2007. His history includes ischaemic heart disease, for which he was treated with atenolol 
from 2005 to 2007, and Type 2 diabetes; he was later started on propranolol 40mg twice a 
day from 2007 for Didanosine-induced portal hypertension. Because of negative cultures 
and neutrophil count < 250 cells/μL, spontaneous bacterial peritonitis was excluded. 
However, some low grade-peritoneal irritation cannot be ruled out because his CRP varied 
from 24 to 258, during 2007-2009, without any other obvious inflammatory cause. He was 
finally diagnosed in July 2009 with sclerosing encapsulating peritonitis (SEP) based on clinical 
features of intestinal obstruction, histology and imaging, including computed tomography 
and magnetic resonance imaging. Propranolol was stopped in November 2009. Because of 
the patient’s severe intestinal obstruction, he was started on parenteral nutrition 2L/day. 
Since then, his CRP has returned to normal levels and there is a great improvement of his 
clinical features. This case demonstrates beta-blockers as a potential cause of SEP, while the 
presence of some low-grade peritoneal inflammation leading to SEP is also very likely.  
Keywords: sclerosing encapsulating peritonitis, beta-blockers, ascites, parenteral nutrition  
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Durchsicht der Literatur und Fallbericht eines Patienten mit 
sklerosierender verkapselnder Peritonitis, der durch parenterale 
Ernährung zu Hause versorgt wird 
 
 
Zusammenfassung 
Wir präsentieren den Fall eines 48-jährigen HIV Patienten, der seit 2007 an periodisch 
auftretendem Aszites leidet. Seine Krankengeschichte beinhaltet zudem eine ischaemische 
Herzerkrankung, die von 2005 bis 2007 mit Atenolol behandelt wurde, und Typ-2-Diabetes; 
später im Jahr 2007 begann man aufgrund einer durch Didanosin herbeigeführte Portalen 
Hypertension, ihm zweimal täglich 40 mg Propanolol zu verabreichen. Aufgrund negativer 
Blutkulturen und einer Neutrophilenzahl < 250/μl wurde eine Spontan bakterielle Peritonitis 
ausgeschlossen. Allerdings kann eine leichte Peritoneale Irritation nicht ausgeschlossen 
werden, da sein CRP von 2007- 2009 ohne jegliche andere offensichtliche 
Entzündungsursache zwischen 24 und 258 schwankte. Schließlich wurde bei ihm im Juli 2009 
eine sklerosierende verkapselnde Peritonitis (SEP) diagnostiziert, basierend auf klinischen 
Merkmalen eines Darmverschlusses, Histologie und Bildgebung, einschließlich einer 
Computer-Tomographie und einer Magnetresonanz-Tomographie. Propanolol wurde im 
November 2009 abgesetzt. Aufgrund des schwerwiegenden Darmverschlusses wurde beim 
Patienten 2l/Tag parenterale Ernährung angesetzt. Seitdem befindet sich sein CRP wieder 
auf normalem Niveau und seine klinischen Merkmale haben sich enorm verbessert. Dieser 
Fall zeigt, dass Beta-Blocker eine potentielle Ursache für SEP darstellen, jedoch gleichzeitig 
nicht ausgeschlossen werden kann, dass das Vorhandensein einer leichten peritonealen 
Entzündung zu einer SEP führt. 
Schlüsselwörter: Sklerosierende verkapselnde Peritonitis, Beta-Blocker, Aszites, parenterale 
Ernährung 
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Review of the literature and description of a case of 
Sclerosing Encapsulating Peritonitis requiring home 
parenteral nutrition 
 
 
Introduction 
Peritonitis is still considered to be a disease with high morbidity and mortality, despite the 
increase of knowledge in the pathophysiology of it. Sclerosing Encapsulating Peritonitis (SEP) 
is a severe kind of peritonitis, relatively frequent in subjects submitted to peritoneal dialysis 
during the last 5 years [1-2]; other causes of the disease are shown in Table 1 [2]. 
 
Table 1. Classification of SEP.[2] 
Primary (idiopathic) SEP 
1. Adolescent form 
2. Adult form 
Secondary SEP 
1. Systemically induced by: 
A. Beta adrenergic blocking agents 
I. Practolol 
II. Timolol 
III. Propanolol 
B. Exposure to asbestosis 
2. Induced by local irritants: 
A. Abdominal trauma 
B. Peritoneal dialysis (most common known cause) 
C. Peritoneovenous shunt 
D. Ventriculoperitoneal shunt 
3. Induced by possible local and/or systemic irritants 
A. Peritoneal sarcoidosis 
B. Familial Mediterranean fever 
4. Carcinoid syndrome 
 
 
SEP is a rare cause of intestinal obstruction that is characterized by a thick, white, fibrous 
membrane formation in the peritoneum that partially or completely encases the bowel 
loops (abdominal cocoon) [3]. Its treatment involves surgery for dealing with the 
obstruction, administering steroids and immunosuppressants, while there are only few cases 
describing the use of total parenteral nutrition (TPN) given as therapy for the management 
of SEP have been described (Kawanishi, many articles, Rajani) [4-5]. 
We present a case and review the literature of SEP associated with spontaneous bacterial 
peritonitis, beta blocker use (propranolol and atenolol), discussing the presentation, 
aetiology and management of this rare condition, by signifying the benefits of parenteral 
nutrition along with their standard treatment. 
 
Case Report 
This 48-year old patient presented to our hospital in August 2007 for investigation of ascites, 
noted at emergency laparotomy earlier in June 2007 (for incarcerated umbilical hernia). He 
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has a history of ischaemic heart disease (myocardial infarction and 2 angioplasties in 2006), 
treated with atenolol from 2005 to 2007, diabetes and HIV infection since 1999, treated with 
Highly Active Anti-Retroviral Therapy (HAART). He was on Didanosine (DDI) until April 2007, 
which was then stopped. He was treated with an initial ascitic tap which was negative for 
spontaneous bacterial peritonitis (SBP), and was a transudate with neutrophil count less 
than 250/ml. Gram stain and mycobacterial cultures were negative on more than one 
occasion; bone marrow stain and culture for acid fast bacilli were also negative. Auto-
antibody screening for HepB, HepC, HHV-8, and autoimmune diseases were all negative. 
There was no evidence of heart failure evident on ultrasound (2009) or history of alcohol 
misuse. Then he went to have an ultrasound guided ascitic drain (3.5L removed) and 
ultrasound guided liver biopsy.  
The liver biopsy showed probable cirrhosis but a nodular regenerative hyperplasia could not 
be excluded. Macrophages with lipofuscin were seen and this would imply that, whatever 
the agent causing the cirrhosis, this had been withdrawn. So DDI-induced liver damage was 
put as a diagnosis. On the same admission he had an Oesophageal-Gastroduodenal 
endoscopy which showed 3 barely noticeable oesophageal varices, 2 shallow gastric ulcers, 
portal hypertensive gastropathy and duodenitis. He was prescribed spironolactone for the 
ascites and discharged. Other medications prescribed were Aspirin, Pravastatin, Ranitidine, 
and Propranolol 40mg bd. Because of painful gynaecomastia, spironolactone was switched 
to Amiloride in January 2008. 
In April 2008, his ultrasound showed an abnormal echotexture in the liver and splenomegaly. 
In June 2008, he went to have another liver biopsy, which demonstrated moderate to severe 
fibrosis but was not reported as being consistent with nodular regenerative hyperplasia. 
 In January 2009, he was noted having ongoing problems with recurring ascites in spite of 
being on Amiloride; for that reason he was considered to be a potential candidate for pre-
transplant assessment since his CD4 had been relatively acceptable and his HIV viral load 
was always very low or undetectable in some instances. Also, his propranolol was changed 
to atenolol. 
In February 2009, abdominal computed tomography (CT) images confirmed ascites and an 
enlarged spleen as well as an irregular lesion in the left lobe of his liver and one in the right 
lobe of his liver. These were thought to be non-specific findings and it was not felt that he 
would need any course of investigation or treatment at that time. His recurring episodes of 
ascites continued to be challenging so he was changed from Amiloride to Furosemide. 
Because of failure to control his ascites, in May 2009 he was given a combination of 
Spironolactone 100 mg once a day plus 40 mg of Furosemide once a day.  
On 20 May 2009, the patient was admitted with abdominal pain and distention of 12 hours 
duration prior to admission; due to his history of cirrhosis this was attributed to ascites and 
3L were drained. The pain however continued to be a problem after drainage and an 
abdominal x-ray showed dilated loops of small bowel; at that time he was passing flatus and 
faeces throughout his admission and never showed any signs of peritonitis. Although his 
white cell count was normal, his CRP was around 80 and an inflammatory or infective cause 
of his small bowel pathology was suspected (Figure 1). Colonoscopy was performed which 
unfortunately could not reach the site of subacute obstruction in order to perform a 
terminal ileum biopsy. Due to the patient’s history of ascites, elective laparoscopic surgery 
was not recommended due to the possibility of fistula formation with presence of ascites. In 
May-June 2009, CT and Magnetic Resonance Imaging (MRI) showed evidence of mechanical 
obstruction (Figure 2 and 3). The proximal small bowel was dilated down to a “mass” of 
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collapsed loops within the right iliac fossa involving the terminal ileum. The morphology of 
this collapsed section was unchanged over the last 3 weeks and therefore suspicious of a 
fixed band. The peristalsis views showed no real evidence of movement within the collapsed 
segment. The dilated loops were oedematous. In July 2009 his renal function seemed to 
decline and continued to have recurrent episodes of abdominal pain, distention, and 
vomiting. Because of these episodes, he was admitted in July 2009 and discharged in 
November 2009. In July 2009, he had complete bowel obstruction which necessitated 
surgical laparotomy. Adhesiolysis was performed by dissecting fibrous tissue releasing the 
small bowel attached to the peritoneum, without any bowel resection. On inspection a thick 
white fibrous layer was noted (abdominal cocoon) and peritoneal biopsy showed dense 
hyaline fibrosis and chronic inflammation with no granulomas and no suggestive features of 
tuberculosis; no small bowel biopsy was taken at that stage. He was finally diagnosed with 
SEP, based on previous CT and MRI images, clinical and laparotomy features. On his 
discharge, beta-blocker use was permanently stopped. 
For his small bowel obstruction, nasogastric (NG) tube aspirations were attempted but he 
could not tolerate NG feeding, due to persistent abdominal pain post-feeding in the 
presence of chronic sub-acute bowel obstruction. Therefore he was started on daily 
parenteral nutrition 1.5L/day in September 2009. His prescription was Nitrogen 11.4g, 
Glucose 800 Kcal, Lipid 550kcal, Sodium 100mmol, Potassium 20 mmol, Calcium 5mmol, 
Magnesium 5mmol, Phosphate 17mmol, Trace Elements-Additrace® 1 vial and Vitamins-
Cernevit® 1 vial, compounded in a multilayer bag. His subsequent subscriptions are shown in 
Table 1. He suffers from episodes of hyperkalaemia (reaching 6.4 mmol/L), precipitated by 
spironolactone use, renal impairment and parenteral nutrition with potassium, thus needing 
regular adjustments. Today we have managed to reduce his daily PN to 1.5L/day. 
Since the treatment of his intestinal obstruction and the initiation of parenteral nutrition, his 
CRP levels have greatly decreased to normal (last CRP in 2011 was 3 mg/L), compare to 
previous levels around 90. At present he is on home parenteral nutrition with a Hickman-line 
inserted. He was started on prednisolone for SEP but no dramatic effect has yet been seen.  
 
Table 2. Home Parenteral Nutrition Prescriptions 
Ingredients Date 
 25/10/09 3/11/09 7/4/10 24/5/2010 14/09/10 27/1/2011 4/7/11 
Total Volume (ml) 1500 1600 1550 1500 1500 1500 1500 
Nitrogen(g) 11.4 12.85 12.85 8.25 9 9 8.25 
Glucose (Kcal) 800 1000 800 800 800 800 800 
Lipid (Kcal) 550 650 550 550 500 500 500 
Sodium (mmol) 100 100 100 100 30 50 50 
Potassium (mmol) 20 0 20 0 20 10 10 
Calcium (mmol) 5 5 5 5 5 5 5 
Magnesium (mmol) 5 5 5 5 5 5 5 
Phosphate (mmol) 17 17 17 17 17 17 17 
Trace Elements 
Additrace
®
 (vials) 
1 1 1 1 1 1 1 
Vitamins Cernevit
®
 
(vials) 
1 1 1 1 1 1 1 
Daily infusion compounded in multilayer bag 
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Discussion 
SEP, first described in 1907 [6], is a rare cause of intestinal obstruction caused by thick white 
fibrous tissue formation in the peritoneum that encase and subsequently cause partial or 
complete intestinal obstruction (abdominal cocoon syndrome). The most common identified 
cause of this rare condition is continuous ambulatory peritoneal dialysis but other causes 
like beta blockers could be a cause as well (Table 1) [7-8]. Other associations reported in the 
literature include ovarian thecomas, tuberculous pelvic inflammatory disease, 
ventriculoperitonealshunts, systemic lupus erythematosus, orthotopic liver transplantation, 
protein S deficiency, ovarian cysts, keratoconjunctivitis sicca syndrome and various beta 
adrenergic blocking agents [3, 5, 9-13]. 
The pathogenesis of SEP is not fully understood, but it is believed that chronic peritoneal 
irritation by agents that cause serositis or previous episodes of peritonitis results in 
mesothelial cell loss which leads to fibrous fibroneogenesis, which is the hall mark of SEP [5, 
14]. It is suggested that it goes through three phases: an initial inflammatory stage with 
eleveated CRP, followed by the encapsulating stage with the appearance of ileus and the 
ileus stage where bowel obstruction progresses (Kawanishi 2005). The exact mechanism by 
which beta blockers induce sclerosing peritonitis is unknown, but two suggested hypotheses 
include a possible allergic type reaction to the class of drug or perhaps an excess production 
of intraperitoneal collagen, which has been shown to be induced by these agents [2, 14]. 
Several theories tried to explain this condition: when it was first described in adolescent girls 
from tropical and subtropical countries, this suggested retrograde menstruation as a cause 
[15], or retrograde viral infection via fallopian tubes [16], but appearance of the disease in 
males and older ages groups discards this hypothesis [17-18]. 
The presentation of SEP can be quite challenging ranging from abdominal pain, nausea, 
vomiting and vague symptoms to frank intestinal obstruction, most of the symptoms being 
related to partial small bowel obstruction. SEP can also present with recurrent ascites or as 
an abdominal mass. Although the diagnosis is most commonly made at laparotomy, 
occasionally it is suspected on radiological imaging [19]. On CT scan, SEP can appear as 
peritoneal thickening or calcification, loculated fluid collections or matting of the small 
bowel. Thickening of the small bowel loops and calcifications of the liver capsule, spleen, 
posterior peritoneal wall or bowel can also be seen [20]. Ultrasound and magnetic 
resonance imaging have also been useful in making this diagnosis [19]. 
Our patient developed SEP in the absence of peritoneal dialysis and did not seem to have 
any of the previous conditions linked to SEP. However, he was on different beta blockers 
(propranolol and atenolol) from 2005 and none of his other medications seem to be linked 
to SEP. He was also on anti-retroviral medication, but there doesn’t seem to be any 
causative link with the pathogenesis of SEP (Rivera 2007, Mesquita 2007). So his use of beta-
blockers seems to be a possible cause of the SEP, which is consistent with the literature [3]. 
The classic beta blocker that was associated with SEP is practolol in 1974 [13], being 
withdrawn from the market in 1975. Since then many case reported with other beta 
blockers like atenolol propranolol, timolol, metoprolol and sotalol [3, 21]. Karla et al. [3] 
described 2 patients who were receiving propranolol for 2 years and 2 months respectively 
and both developed SEP. Their doses were 320 mg and 80mg day, showing that the 
development of SEP is independent of the dose. Both patients recovered. 
Another cause we believe could lead to SEP is the presence of culture negative, neutrophil 
negative low-grade inflammatory peritoneal irritation. Although the patient was never 
diagnosed with spontaneous bacterial peritonitis (SBP) in terms of standard criteria, he 
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constantly presented with high CRP for which the cause could not be identified (Kawanaishi 
2005, 2002). We believe that there was some very low grade inflammatory process in the 
ascitic fluid which finally led to SEP (peritoneal irritation). Evans et al. [22] noted that about 
half of his patients with SBP (n=15) from his cohort of patients with cirrhotic ascites (n=427), 
had culture negative neutrocytic ascites, as described by Runyon and Hoefs [23]. This low 
grade inflammation could be associated with development of serositis leading inevitably to 
sclerosing peritonitis [5]. SEP after SBP was also reported in a 36-year old woman 3 weeks 
after she delivered her baby [24]. A recent meta-analysis showed that studies use various 
cut-off points for ascetic neutrophil count (>500 or >250 cell/μL). The most accurate 
parameters to diagnose SBP were an ascitic neutrophil count of greater than 500 cells/μL 
(summary LR, 10.6; 95% CI, 6.1-18.3), even though antibiotics are usually started when 
neutrophils are greater than 250 cells/μL. Although an ascitic neutrophil count of 250 
cells/μL or less lowers the likelihood of SBP (summary LR, 0.20; 95% CI, 0.11-0.37), this is not 
zero [25]. 
The next original point in our case is the improvement of our patient’s overall condition 
since he went on parenteral nutrition (PN) from August 2009. Taking into account the worse 
nutritional state by a medical history of 2 years with ascites, probable cirrhosis and mild to 
severe systemic inflammation of unknown origin, aggravated by a subileus/ ileus with 
abdominal pain, distension and vomiting over a period of 3 months, PN expectably has a 
positive effect on the outcome of the patient and his course of disease. This coincides with 
the treatment of his intestinal obstruction which most possibly lowered his CRP levels to 
normal. His CRP levels have gone markedly down to normal and have remained stable over 
the last year. There is a possibility that certain PN nutrients are lowering his CRP, although 
this seems initially unlikely.. Few papers discuss the importance of prescribing PN in the 
treatment of SEP (4,5, Rajani, Kawanishi,  urian). Two cases highlight the importance PN: one 
in a patient who had renal failure and was receiving CAPD for more than 3 years [4] and one 
in a woman with associated ovarian cysts and kerato-conjunctivitis sicca syndrome [5]. The 
first patient suffered from intestinal failure associated with obstruction episodes and small 
bowel resection (Pusateri), while the second suffered predominantly from obstruction 
related intestinal failure. Kawanishi notes the importance of treating the encapsulating stage 
of SEP with TPN, which relieves the intestine from the obstruction episodes. 
The treatment of SEP is mainly surgical with lysis of the adhesions at laparotomy. A 
retrospective analysis of 32 patients with this condition as done to determine the best 
surgical management comparing membrane resection, enterolysis, partial excision of the 
membrane, intestinal resection and exploratory laparotomy only. Membrane resection 
resulted in less patients having persistent bowel obstruction or death and the study 
recommended this be attempted when feasible. No surgical treatment was recommended in 
cases of associated ascites, asymptomatic sclerosing peritonitis, or sub-acute intestinal 
obstruction [2-3, 26]. 
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Figures 
 
Figure 1. A. Blood Markers of the patient. The time point where PN was introduced is shown. 
B. Additional Blood Markers 
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Figure 2. CT scans showing the 
encapsulated bowel mass and fibrotic 
peritoneum 
 
 
 
Figure 3. MRI scans showing the 
encapsulated bowel mass and fibrotic 
peritoneum 
 
 
 
